Literature DB >> 9827928

Human myeloma cell apoptosis induced by interferon-alpha.

T Otsuki1, O Yamada, H Sakaguchi, A Tomokuni, H Wada, Y Yawata, A Ueki.   

Abstract

Although there have been reports regarding the clinical effectiveness of IFN alpha in the treatment of myeloma patients during this decade, its biological effects on human myeloma cells have still not been clarified. Recently, apoptosis has been considered as one of the most important mechanisms in the programmed cell death of malignant tumour cells induced by chemotherapeutic agents or cytotoxic immunological defence in malignancy-carrying hosts. Among the several pathways which function to induce apoptosis, Fas and the Fas ligand system have been thought to play an important role in inducing tumour-cell apoptosis, particularly in immunological prevention. In this study we investigated myeloma cell apoptosis induced by IFN alpha using five human myeloma cell lines which were established without any additional supplementation of IL-6. In addition, the mRNA expression levels of apoptosis-related genes employing the reverse transcriptase-polymerase chain reaction (RT-PCR) were also analysed with the KMS-12-PE cell line, which was the most sensitive of the five cell lines in terms of apoptosis induced by IFN alpha. Based on the results, it was determined that IFN alpha induced myeloma cell apoptosis in a dose-dependent manner, but the sensitivity to IFN alpha in the cell lines examined varied and one cell line revealed growth stimulation by IFN alpha. In addition, the apoptosis induced by IFN alpha did not seem to be mediated by the Fas/Fas ligand pathway. Finally, the IL-6, IL-6R, IRF1 and IRF2 genes were up-regulated in KMS-12-PE cells cultured with IFN alpha. Therefore these genes may play an important role during apoptosis induced by IFN alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827928     DOI: 10.1046/j.1365-2141.1998.01000.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Regulation of apoptosis by type III interferons.

Authors:  W Li; A Lewis-Antes; J Huang; M Balan; S V Kotenko
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

2.  Analysis of apoptosis of memory T cells and dendritic cells during the early stages of viral infection or exposure to toll-like receptor agonists.

Authors:  Kapil Bahl; Anette Hüebner; Roger J Davis; Raymond M Welsh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

3.  The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells.

Authors:  Hwa Young Yim; Young Yang; Jong-Seok Lim; Myeong Seok Lee; Dong-Er Zhang; Keun Il Kim
Journal:  Biochem Biophys Res Commun       Date:  2012-06-05       Impact factor: 3.575

4.  Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis.

Authors:  Akiko Takata-Tomokuni; Ayako Ueki; Mieko Shiwa; Yumika Isozaki; Tamayo Hatayama; Hironobu Katsuyama; Fuminori Hyodoh; Wataru Fujimoto; Hiroaki Ueki; Masayasu Kusaka; Hisashi Arikuni; Takemi Otsuki
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

5.  G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Authors:  Venugopalan Cheriyath; Keith B Glaser; Jeffrey F Waring; Rachid Baz; Mohamad A Hussein; Ernest C Borden
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.

Authors:  Kenichiro Yata; Takemi Otsuki; Osamu Yamada; Hideho Wada; Yoshihito Yawata; Takashi Sugihara
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

7.  Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

Authors:  H Kunisue; J Kurebayashi; T Otsuki; C K Tang; M Kurosumi; S Yamamoto; K Tanaka; H Doihara; N Shimizu; H Sonoo
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 8.  Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Authors:  Wassilis S C Bruins; Sonja Zweegman; Tuna Mutis; Niels W C J van de Donk
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

9.  General mechanism of JQ1 in inhibiting various types of cancer.

Authors:  Guojuan Jiang; Wanglong Deng; Yang Liu; Chengde Wang
Journal:  Mol Med Rep       Date:  2020-01-10       Impact factor: 2.952

10.  Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.

Authors:  Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger
Journal:  J Vet Intern Med       Date:  2007 Nov-Dec       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.